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Abstract
Background: The immune system exerts a diversifying selection pressure on HIV through cellular, humoral and innate
mechanisms. This pressure drives viral evolution throughout infection. A better understanding of the natural immune
pressure on the virus during infection is warranted, given the clinical interest in eliciting and sustaining an immune
response to HIV which can help to control the infection. We undertook to evaluate the potential of the novel HIV-induced,
monocyte-derived factor visfatin to modulate viral infection, as part of the innate immune pressure on viral populations.
Results: We show that visfatin is capable of selectively inhibiting infection by R5 HIV strains in macrophages and resting
PBMC in vitro, while at the same time remaining indifferent to or even favouring infection by X4 strains. Furthermore,
visfatin exerts a direct effect on the relative fitness of R5 versus X4 infections in a viral competition setup. Direct interaction
of visfatin with the CCR5 receptor is proposed as a putative mechanism for this differential effect. Possible in vivo relevance
of visfatin induction is illustrated by its association with the dominance of CXCR4-using HIV in the plasma.
Conclusions: As an innate factor produced by monocytes, visfatin is capable of inhibiting infections by R5 but not X4 strains,
reflecting a potential selective pressure against R5 viruses.
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Introduction
Background
Virus-host interactions in Human Immunodeficiency Virus
(HIV) infection are characterised by a continuous arms race
between the immune system and the virus. HIV is targeted by an
immune response from the very first weeks of the acute phase, and
the resulting immune pressure drives viral evolution throughout
the infection. This diversifying selection manifests prominently
(though certainly not exclusively) at the level of the variable
regions of the envelope (Env) gene [1]. One example of such
diversifying evolution of Env is the development of the so-called
coreceptor switch, which entails the change in preferential
coreceptor usage (determined by the V3 region of Env [2]) of
the virus for CCR5 to CXCR4 in ,50% of all HIV subtype B
infected patients. The switch is associated with increased rates of T
lymphocyte depletion and rapid progression to AIDS. Neverthe-
less, the viral and immune parameters underpinning this switch
remain a matter of debate [3,4].
Most studies concerning immune pressure on HIV have focused
on either the adaptive cellular or the humoral arm of the immune
system. Increasingly, however, the important influence of
restriction factors and innate immunity on viral infectivity is
recognised. Viral evolution driven by cellular responses typically
hinges on viral escape from cytotoxic T lymphocyte (CTL) activity
by introducing mutations in epitopes recognised by Human
Leukocyte Antigen (HLA) class I molecules [5,6,7]. Humoral
responses on the other hand result in neutralising antibodies
targeted at Env epitopes, which drive the virus to rapid mutation
of Env to escape this neutralising activity [8,9]. A possible
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monocytes and macrophages, to selective pressure on HIV
infection is much less well documented. Nevertheless, in vivo
and in vitro infection of macrophages by HIV has been extensively
documented since the early days of the HIV pandemic [10,11],
and while they exhibit a marked resistance to the cytopathic effects
of HIV which occur in T lymphocytes [12], a wealth of
macrophage dysfunctions contributing to HIV pathogenesis have
been described[13]. In particular, monocytes/macrophages rep-
resent one of the major viral reservoirs during infection [14], due
to their longevity [15,16], their extended phase of viral
productivity [17] and the relative ease by which they disseminate
HIV to other cells [18]. As a primary reservoir for HIV and as
major effectors of cellular immunity, macrophages are thus
uniquely placed to exert an evolutionary pressure on viral
development, in addition to the humoral and cellular arms of
the immune system.
A better understanding of the natural selective pressure on the
virus during infection may shed light on the variability in immune
control between individual patients. Specifically for a poorly
understood phenomenon as the coreceptor switch, identification of
novel factors involved in the immune pressure on HIV could
contribute to the fine-tuning of dynamical models currently under
development (e.g. [19]), in addition playing a potential role as e.g.
predictive biomarkers. As mentioned above, cells of monocyte/
macrophage lineage seem to be interesting and hitherto incom-
pletely explored candidates as a source of such factors.
In a previous transcriptome analysis comparing monocytes of
therapy-naı ¨ve HIV patients and healthy control donors, we
demonstrated an increase in both visfatin plasma levels and
visfatin monocyte mRNA and protein expression in HIV patients
[20]. Additionally, we described the inhibitory effect of visfatin on
infections by the lab strain HIVBaL and the biological clones
HIV968-2 and HIV968-3, all of which are R5 strains. As leukocytes
have since been shown to represent a major source of active
visfatin in other models of pathology and the documented increase
may thus be of physiological relevance [21], we evaluate here
whether visfatin is equally capable of inhibiting other strains of
HIV, including X4 viruses, in the interest of further characterising
the potential immune pressure exerted by this novel antiviral
factor.
Methods
Ethics Statement
The study was approved by the Institutional Review Board of
the Institute of Tropical Medicine and written informed consent
was obtained from all donors.
Sample Collection
20 ml blood samples were collected in EDTA-tubes from 22
therapy-naı ¨ve HIV subtype B seropositive outpatients from the
HIV Clinic of the Institute of Tropical Medicine in Antwerp,
Belgium. Peripheral blood mononuclear cells (PBMC) were
separated via a Lymphoprep (Axis Shield, Dundee, United
Kingdom) gradient and plasma was concomitantly aspirated and
stored at 280uC. Monocytes were purified from the PBMC
fraction using the negative selection-based Monocyte Isolation Kit
II from Miltenyi-Biotec (Bergisch Gladbach, Germany), according
to the manufacturer’s instructions. Yields were minimally 2610
6
monocytes with a purity . 85%, as verified through flow
cytometry. For RNA extraction, monocytes were immediately
lysed in Trizol (Invitrogen, Carlsbad, CA, USA), and Trizol pellets
were stored at 280uC.
RNA Isolation and Real-time Semi-quantitative PCR
Total RNA was prepared from the Trizol pellets by chloroform
extraction, as per the manufacturer’s recommendations. Ten
randomly selected samples were checked for integrity on a
BioAnalyzer (BioRad, Hercules, CA, USA): no protein contam-
ination or degradation of RNA was detected. mRNA expression of
visfatin, normalised to the expression of the housekeeping gene
GAPDH, was analysed using real-time semi-quantitative PCR
(RT-qPCR) as described previously [20].
Cell Isolation
For in vitro infection experiments, monocytes were isolated
from PBMC obtained from buffy coats of healthy donors of the
Blood Transfusion Center of Antwerp by counterflow elutria-
tion, as described previously [22]. These cells were then
differentiated to monocyte-derived macrophages (MDM) dur-
ing 7 days in RPMI 1640 medium (Bio-Whittaker, Verviers,
Belgium) supplemented with 10% bovine foetal calf serum
(FCS; Biochrom, Berlin, Germany), penicillin (100 U/ml) and
streptomycin (100 mg/ml) (Roche) and 40 ng/ml M-CSF
(PeproTech, London, United Kingdom) at 37uC and 5.0%
CO2.H a l fo ft h em e d i u mw a sr e p l a c e da f t e r4d a y so fc u l t u r e .
Cells were harvested and used for experiments in the same
medium (without M-CSF). All experiments were repeated with
cells from six different donors. Recombinant visfatin was
obtained from PeproTech. The recombinant protein batches
contained , 0.01 ng/mgL P S ,a sa s s e s s e db yq u a n t i t a t i v e
chromogenic limulus amoebocyte lysate assay (QLAL) (Bio-
Whittaker). Viability of cells treated with recombinant visfatin
was evaluated using the cell proliferation agent WST-1 (Roche)
according to the manufacturer’s instructions: no appreciable
effect on cell viability was found at the concentrations used
(data not shown). Production of endogenous visfatin in MDM
and PBMC cultures at the RNA and protein level was not
found to be modulated by in vitro HIV infection (data not
shown).
Viral Replication
For viral replication experiments, MDM or resting PBMC were
plated in 96-well plates at 7.5610
5 cells/ml and pre-treated with
recombinant visfatin (200 ng/ml) or with medium alone for
control cultures for 24 hours at 37uC and 5.0% CO2. Then, virus
was added as dilution series in sixfold and incubated for 2 hours
(24 hours for resting PBMC), again at 37uC and 5.0% CO2. Cells
were then washed 3x to remove unbound virus and incubated for
14 days (in the presence of IL2 (5 ng/ml) (Roche) for resting
PBMC to rescue the infection). Productive infection was
monitored via an in-house developed p24 antigen ELISA, as
described elsewhere [23]. Viral infection was quantified as the
TCID50 (50% tissue culture infectious dose) value, which was
calculated by the method of Reed & Muench [24]. Viral infection
in untreated cultures is documented in table 1 for reference
purposes.
p24 Production
For specific measurement of p24 production, cells were
prepared in the same way as for viral replication experiments.
Virus was added in sixfold at an adjusted MOI of 0.1 (titrated
individually for untreated and treated cells, i.e. with a viral dose
adapted to the specific treatment of the cells) and incubated for 2
hours (24 hours for resting PBMC), again at 37uC and 5.0%
CO2. p24 production was quantified via an in-house developed
p24 antigen ELISA, as described elsewhere [23].
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For time of addition experiments, the MT-2 setup published
elsewhere was used [25]. MT-2 cells were cultured in RPMI 1640
medium (Bio-Whittaker) supplemented with 10% FCS (Bio-
chrom), penicillin (100 U/ml) and streptomycin (100 mg/ml)
(Roche). 10
4 MT-2 cells were seeded and infected with HIVBaL
and HIV968-2 at a 0.01 MOI. Cells were incubated with the virus
for the indicated times at 37uC and 5.0% CO2 before addition of
recombinant visfatin (to a final concentration of 200 ng/ml) or
medium alone for the control cultures. Cells were then incubated a
further two hours at 37uC and 5.0% CO2 and were then washed
to remove visfatin and free virus. Fresh medium was added and
cultures were incubated for four days at 37uC and 5.0% CO2
before assessment of p24 production by ELISA [23].
Dose-response Infection Experiments
For dose-response experiments, MDM were prepared in the
same way as for viral replication experiments – pre-treatment with
visfatin was done with the indicated concentrations (range 0.02-
200 ng/ml) or with medium alone for control cultures. Virus was
added in sixfold at a MOI of 0.1 (virus titrated on untreated cells)
and p24 production was quantified via an in-house developed p24
antigen ELISA, as described elsewhere [23].
Viral Competition Assay
To assess the relative fitness, defined as the potential for viral
reproduction within a given environment, of isogenic viruses
differing only in their Env sequences, in this context to compare
the fitness of isogenic R5 versus X4 viruses, an assay was
developed using fluorescently tagged (eGFP/DsRedExpress)
replication-competent chimeric viral constructs. Existing replica-
tion-competent constructs based on the HIVNL43 backbone, with
the eGFP or DsRedExpress sequence in concatenation with an
internal ribosome entry site, were a kind gift by Dr. Kevin Arie ¨n
and Dr. Bruno Verhasselt (UGent) [26]. Through molecular
cloning, the HIVNL43 Env sequences in these constructs were
replaced with a restriction (linearization) site. Following lineariza-
tion, amplified Env sequences of interest (HIVBaL, HIVHxB2,
HIV943-1, HIV943-3) were cloned into the constructs using
InFusion (Clontech, Mountain View, CA, USA) technology.
In this fashion, plasmids for four eGFP-labelled and four
DsRedExpress-labelled chimeric viral constructs were generated
(HIVBaL,H I V HxB2,H I V 943-1,H I V 943-3). Infectious viruses were
generated by transfection of HEK293 T cells [27], as described
elsewhere [28]. Since productive infections with these viruses
could be established in the Jurkat [29] and SupT1[30] T
lymphocyte cell lines but not in primary cell cultures, all
competition experiments were performed in the Jurkat T cell
line.
Infections were performed by plating Jurkat T cells in 48-well
plates at 0.5610
6 cells/ml and 200 ml/well in RPMI 1640
medium (Bio-Whittaker) supplemented with 10% FCS (Bio-
chrom), penicillin (100 U/ml) and streptomycin (100 mg/ml)
(Roche), 50 mg/ml L-glutamine (Lonza, Basel, Switzerland) and
0.2 mg/ml geneticin (Invitrogen), adding infectious viruses at a
multiplicity of infection (MOI) of 0.1, either as a mono- or as a
double infection, to a final volume of 400 ml/well and incubating
for 24 hours at 37uC and 5.0% CO2. Cells were then washed 3x
to remove unbound virus and incubated further. At day 3, 7, 10
and 14 post-infection, 200 ml cell suspension was harvested for
flow cytometric analysis and the volume was replenished to
400 ml. At day 7, after harvesting, the cultures were supplemented
with either visfatin (200 ng/ml), maraviroc (5 nM) or normal
medium as control. With each subsequent replenishment of the
medium, these concentrations were maintained.
An example of the calculation of the relative R5 versus X4
f i t n e s si sp r o v i d e di nf i g u r e1for the competition between an
eGFP labelled BaL-derived and a DsRedExpress labelled HxB2-
derived virus. This example documents the calculation at day 7
post infection – all calculations were done in the same way for
each individual time point. The total number of fluorescent-
positive cells (eGFP or DsRedExpress) for a specific virus in the
double infections was normalised by the number of fluorescent-
positive cells in the mono-infection of that virus, establishing the
overall viral infection rate in the double infections (equations A–
B). The ratio of the R5 over the X4 viral infection rate was
taken as the relative R5 versus X4 fitness (equation C). All
experiments were conducted in a colour-flipped setup (i.e. R5-
eGFP and X4 DsRedExpress in parallel with R5-DsRedExpress
and X4-eGFP) to avoid any potential bias introduced by the
fluorescent labels.
BaL production(X)~
(R2zR3)
double
R2mono ~
18:9z6:1
10:8
~2:31 ðAÞ
HxB2 production(Y)~
(R1zR3)
double
R1mono ~
17:8z6:1
20:3
~1:18 ðBÞ
Relative fitness of BaL vs: HxB2~
X
Y
~
2:31
1:18
~1:97 ðCÞ
Table 1. Mean infectivity of HIV strains in untreated MDM and PBMC.
Coreceptor usage HIV strain log TCID5/ml (MDM) log TCID50/ml (PBMC)
R5 BaL 4.07 6.20
R5 968-2 2.78 3.04
R5 968-3 2.90 3.28
X4 IIIB 1.06 5.10
X4 968-1 Non-infectious 2.98
X4 968-4 Non-infectious 3.11
TCID50: 50% tissue culture infectious dose; MDM: monocyte-derived macrophage; PBMC: peripheral blood mononuclear cell.
doi:10.1371/journal.pone.0035074.t001
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Interaction of visfatin with CCR5 was assessed by Surface
Plasmon Resonance (SPR) using a T100 Biacore instrument (GE
Healthcare, Buckinghamshire, UK). The setup consisted of a CM5
chip on which an antibody raised against the 5His tag (Qiagen,
Valencia, CA, USA) was immobilized, using amine coupling
chemistry. This antibody (,10000 Resonance Units) could
capture ,5000 RU of recombinant His-tagged insect-cell
expressed CCR5[31], solubilized from membranes using a
detergent mixture of DDM, CHAPS, CHS, and DOPC[32] at
pH 7: this solution was injected over a surface constituted of
amine-coupled anti-His-tag antibody. The capture of CCR5 was
thus achieved through a 5His tag on its C-terminal (the
intracellular part of the receptor). In this setup, CCR5 was
recognized by the conformation-dependent 2D7 antibody (mouse
anti-human CD195, BD Pharmingen, Franklin Lakes, NJ, USA),
which recognizes well-folded (not denatured) ECL2 on the extra-
cellular side (data not shown). The approach is conceptually
similar to that discussed in [33].
In this setup, CCR5 was shown to be able to bind the
conformation-dependent antibody 2D7 (mouse anti-human
CD195, BD Pharmingen, Franklin Lakes, NJ, USA; data not
shown). Experiments with visfatin (Peprotech) were performed at
least twice using a flow rate of 50 mL/min during an association
phase of 360 s. The detergent mixture (DDM, CHAPS, CHS, and
DOPC) was present at all steps of the experiment; before, during
and after visfatin injection. Signals were processed with the
Biacore T100 Evaluation Software using double referencing with
both a reference channel (without CCR5) and blank injections
(buffer only).
Viral Isolation and Coreceptor Usage Determination
Coreceptor usage of clinical viral isolates was determined by in
silico prediction algorithms based on Env V3 loop sequences.
Plasma separated from patient blood samples was stored at 280uC
until use. Viral RNA was extracted from 140 ml of patient plasma
using a QIAamp Viral RNA Mini Kit (Qiagen) according to the
manufacturer’s instructions. Reverse transcription was performed
using Expand RT enzyme (Roche Diagnostics, Mannheim,
Germany) and the 3INN2b primer (59-GTGTGTAGTTYTGC-
CARTCAGGG-39). A V3-containing fragment of the Env gene
was amplified from this viral cDNA and the V3 loop was
sequenced using the H1E100 (59-CGGAATTCAGIACAGTA-
CAATGTACACATGG-39) primer. Sequences were analysed
using the Support Vector Machines (SVM) and Charge Rule
algorithms for coreceptor usage prediction (available at http://
genomiac2.ucsd.edu:8080/wetcat/v3.html) [34]. For a limited
subset of samples, predicted coreceptor usage was confirmed by
culturing the dominant virus from plasma samples and performing
U373.CCR5 and U373.CXCR4 infection assays.
Statistical Analysis
Significance of patient data was assessed via nonparametric
Mann-Whitney test. All statistical calculations, including IC50
determination through nonlinear regression analysis, were
performed using GraphPad Prism version 4.01 for Windows
(GraphPad Software, San Diego, CA, USA). All data are
expressed as mean 6 SEM and representative data of at least
three independent experiments is shown, except where
indicated.
Figure 1. Optimization of relative fitness calculations for chimeric virus competitions. Infection of untreated Jurkat cells with BaL- and
HxB2-Env-supplemented pBRNL43 IRES eGFP/DsRedExpress constructs; fluorescence levels were assessed by flow cytometry after 7 days of infection.
A) Live gate; B) regions of eGFP+, DsRedExpress+ and double+; C) eGFP+ cells in BaL mono-infected cultures; D) DsRedEpress+ cells in HxB2 mono-
infected cultures; E) eGFP+, DsRedExpress+ and double+ cells in BaL/HxB2 double-infected cultures.
doi:10.1371/journal.pone.0035074.g001
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Visfatin Differentially Affects Infection/Production by R5
and X4 HIV Strains
Previously, the inhibitory effect of visfatin on infection of MDM
and resting PBMC by the lab strain HIVBaL and the biological
clones HIV968-2 and HIV968-3 was described [20]. To evaluate the
potential of visfatin to contribute to the immune control of
different viral strains, parallel cultures of MDM and resting PBMC
were infected with the lab strains HIVBaL (R5) and HIVIIIB (X4)
and the biological clones HIV968-2 – HIV968-3 (R5) and HIV968-1 –
HIV968-4 (X4). Viral production in visfatin-treated cells was
compared to that in untreated cells from the same donor (taken as
100% production), i.e. each infection experiment was performed
with its own internal control. Infection of MDM and PBMC by
the R5 strains was inhibited by treatment of the cells with visfatin,
as described previously: TCID50 values of R5 strains in MDM
and PBMC were reduced by approximately 1 log and 0.85 log
respectively in the presence of visfatin, indicating a ,90% and
,75% reduction respectively (fig. 2A-B).
Additionally, we measured p24 production by visfatin-treated
and untreated cells after infection. Cell cultures were infected at an
Figure2.ModulationofviralinfectionandproductionofR5andX4HIVstrainsbyvisfatin.Infection ofMDM andrestingPBMC(pre-)treated
with recombinant visfatin (200 ng/ml) by R5 HIVBaL, HIV968-2 and HIV968-3 and X4 HIVIIIB, HIV968-1 and HIV968-4: A-B) TCID50 values were determined using
the method of Reed & Muench[24], based onp24 measurement in culture supernatants of respectively MDM andPBMC. Infection in visfatin treated cells
is expressed as a percentage of infection in untreated control cells from the same donor (a): an infection could not be established in absence of visfatin
treatment; resultsfor sixindependentdonorsareshown;C-D) viral production, asquantifiedbyp24 secretion,14days afterrespectivelyMDMandPBMC
infection with the different strains at 0.1 MOI; means 6 SEM of six independent donors are shown; E) time of addition: MT-2 cells were infected with R5
HIVBaL and HIV968-2 and were treated with visfatin (200 ng/ml) after the indicated times; p24 production was assessed after 4 days of infection; F) viral
production,asquantifiedbyp24secretion,14daysafterMDMinfectionwithR5HIVBaL,HIV968-2andHIV968-3at0.1MOI,inthepresenceofdifferentdoses
of visfatin (dose-response curve). NT: untreated control.
doi:10.1371/journal.pone.0035074.g002
Visfatin Differentially Affects R5 versus X4 HIV
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35074adjusted MOI of 0.1, i.e. titrations were done individually for both
cell types and in presence and absence of visfatin – the viral dose
giving 0.1 MOI in each specific setting was then used. In visfatin-
treated cells in which an R5 infection was established (at an
adjusted MOI of 0.1) the p24 levels were significantly lower than
in untreated cells, albeit to a lesser degree than the inhibition of
infection (fig. 2C-D). These data suggest that visfatin may exert
inhibitory effects at two levels: inhibition of infection as such
(possibly at entry level), and inhibition more downstream of entry.
Time of addition experiments in the MT-2 cell-line were
performed to verify whether the kinetics of visfatin inhibition are
in line with those of a viral entry inhibitor. The rapid reduction in
inhibition when visfatin was added to infected cultures after one
hour or more is suggestive of entry inhibition, though inhibition
was not abrogated completely (fig. 2E), again suggesting a possible
dual effect of visfatin. To correctly assess the inhibitory effect of
visfatin, and to ascertain that the doses needed to establish
inhibition in vitro are compatible with reported serum visfatin
loads of 1-10 ng/ml in vivo[35], a dose-response curve was
established for the HIV968-3 strain (fig. 2G) – p24 levels of
untreated control cells were in the range of those in cells treated
with the lowest dose of visfatin (0.02 ng/ml – data not shown).
Based on these dose-response curves, the EC50 values of visfatin in
MDM were calculated (table 2).
Interestingly, this inhibitory effect was not observed in cells
infected with the X4 strains HIVIIIB, HIV968-1 and HIV968-4.
Infection by HIVIIIB and production of p24 in presence or absence
of visfatin was not affected. Effects on the X4 clones 968-1 and
968-4 were even more pronounced: these clones were not capable
of infecting untreated MDM but could establish a productive
infection in MDM after visfatin treatment (fig. 2A&C). This
differential effect was also observed in PBMC, where visfatin did
not inhibit, and in some donors even augmented, infection by X4
HIV968-1 and HIV968-4. However, in cells which were infected
(adjusted MOI of 0.1 for treated and untreated cells), p24
production was not modulated by visfatin treatment (fig. 2B&D).
Thus, visfatin appears to be capable of applying differential
inhibitory activity on different strains of HIV, seemingly
dependent on the coreceptor usage of these strains.
Visfatin Exerts a Selective Pressure on HIV Favouring X4
Strains
The differential effect of visfatin on R5 versus X4 HIV strains
suggests that it may contribute to a general ‘‘R5 unfavourable’’
environment, favouring development of X4 strains. However,
these observations were based on infection assays using viruses
which differ in more than merely their coreceptor usage.
Additionally, the observed effects in single viral infections do not
necessarily confer a fitness advantage of X4 over R5 viruses, as
effects may be too slight to be of in vivo relevance and the
complexity of viral dynamics in a competitive setup is not
accounted for. We therefore developed an assay for the evaluation
of the relative fitness, defined as the potential for viral
reproduction within a given environment, of quasi-isogenic R5
and X4 viruses, using fluorescently tagged (eGFP/DsRedExpress)
replication-competent chimeric viral constructs into which Env
sequences of interest (R5 and X4 viruses) were cloned.
Here, Env sequences of the lab strains HIVBaL (R5) and
HIVHxB2 (X4) and the clinical isolates HIV943-3 (R5) and HIV943-1
(X4) were used to complement these chimeric viral constructs,
which were competed against each other in Jurkat T cell line
cultures. The clinical isolates were selected for their Env sequence
similarity (as they were isolated from the same patient) and their
relatively matched fitness [36]. After 7 days of competition, visfatin
or the CCR5 antagonist maraviroc (as positive control) were
added to the cultures to evaluate whether they could modulate the
relative fitness of the R5 versus the X4 strains. In all competitions
(Env sequences of lab-attenuated strains and of clinical isolates), a
clear effect on the relative fitness was observed: R5 versus X4
relative fitness decreased as soon as visfatin or maraviroc were
added (fig. 3). In the competitions involving Env sequences from
clinical isolates, effects were most pronounced, with viruses
Table 2. IC50 values of visfatin in MDM for R5 HIV strains.
HIV strain IC50 (95% CI)
BaL 1.24 ng/ml (1.15–1.38)
968-2 1.46 ng/ml (0.44–4.95)
968-3 1.15 ng/ml (0.46–1.12)
IC50: 50% inhibitory concentration.
doi:10.1371/journal.pone.0035074.t002
Figure 3. Relative fitness of R5 versus X4 HIV strains in
presence and absence of visfatin and maraviroc. Flow cytometric
evaluation of infection rates of Jurkat T cells by eGFP and DsRedExpress
chimeric viruses at 0.1 MOI in presence and absence of visfatin (200 ng/
ml) or maraviroc (5 nM): A) HIV943-3 (R5) versus HIV943-1 (X4) and B)
HIVBaL (R5) versus HIVHxB2 (X4). Ratios are depicted of infection rates in
double infections normalised to the mono-infection rates; all infections
were performed in a colour-flipped setup. Mean and SEM were
calculated based on the colour-flipped datasets within each experi-
ment; representative results for three independent experiments are
shown. NT: untreated control.
doi:10.1371/journal.pone.0035074.g003
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after visfatin treatment (fig. 3A). For the competitions involving the
lab-attenuated strains, a significant reduction in the relative fitness
of R5 over X4 viruses was observed, though the R5 viruses
maintained their dominance (fig. 3B). No significant additive
effects of visfatin on maraviroc were observed (data not shown).
Visfatin therefore seems capable of directly exerting a selective
pressure against R5 and favouring X4 viruses.
Visfatin Interacts Directly with the CCR5 Coreceptor
Previously, we demonstrated that visfatin acts on early, pre-
integration events in the R5 viral life cycle, as evidenced by the
reduced integration of proviral DNA in infected cells in the
presence of visfatin [20]. However, we were not able to identify the
inhibitory mechanism underpinning the observed visfatin activity.
In view of the differential effects observed here, we evaluated
whether visfatin could interact directly with the CCR5 coreceptor,
which could provide a mechanistic basis for the observed
inhibition of R5 infection. Binding studies between visfatin and
detergent-solubilised CCR5 were conducted in a SPR setup. A
specific interaction between visfatin and CCR5 was observed
(fig. 4). In accordance with the functional dimerisation of visfatin, a
two-binding site model resulted in an improved fitting of the curve
(as opposed to a 1:1 binding model, fig. 4B-C) and suggested that
the affinity of visfatin for CCR5 was in the nM range, whereas the
KD for the dimerisation would be in the mM range. Consistent
with the hypothesis of visfatin dimerisation on CCR5 after the
binding of the first visfatin monomer, the fitted populations for
both binding sites were approximately 50% each.
Visfatin Expression Correlates with Coreceptor Usage of
Clinical Isolates
In order to establish whether clinical observations support the in
vitro observation that visfatin contributes to an ‘‘X4 favourable’’
environment, the coreceptor usage of dominant plasma viruses in
therapy-naı ¨ve HIV patients was evaluated. Coreceptor usage was
assessed using in silico prediction algorithms based on the
sequence of the variable V3 loop of the HIV Env gene [34].
Out of the 22 samples assessed, six patients turned out to harbour
X4 viruses. For three of these patient plasma samples, viral
culturing was possible and viral coreceptor usage was confirmed
by infection experiments of CCR5- or CXCR4-expressing U373
cells. These samples were matched for age, CD4 T Lymphocyte
count and viral load with R5 samples, again three of which were
confirmed as R5 by in vitro infection experiments.
Visfatin monocyte mRNA expression, as quantified by real-time
qPCR, was compared between these two groups. When patients
were grouped according to the coreceptor usage of their
corresponding plasma viruses, clear differences were found
between the groups at the level of visfatin mRNA expression.
High visfatin expression appeared to correlate with the dominance
of X4 viruses, while low visfatin expression was associated with R5
viruses (fig. 5). As these groups were matched for viral load, the
observed difference cannot be due to higher visfatin expression
resulting from high viral loads in patients having undergone the
coreceptor switch. This correlation reinforces the notion that
visfatin can contribute to an environment which is more
favourable towards X4 HIV than R5.
Discussion
In this study, we further characterised the factor visfatin, which
was found to be induced in monocytes of therapy-naı ¨ve HIV
patients in a previous transcriptome analysis [20]. As we initially
described visfatin as a putative innate antiviral factor induced
during HIV infection based on infections with R5 strains of HIV,
we evaluated the effects of visfatin on MDM and PBMC infection
by X4 strains of HIV, in order to ascertain whether visfatin can
modulate general HIV infection. Our observations suggested that
visfatin can exert a selective pressure on HIV, in that it is capable
Figure 4. Characterisation of visfatin-CCR5 interaction, as
assessed by SPR. Different concentrations of visfatin were injected
sequentially on immobilized CCR5. Vertical dashed lines indicate the
start and end of injection. A) Raw data; B) fitting to a 1:1 binding model
and C) to a two binding site model, with respective KD and X
2 values.
doi:10.1371/journal.pone.0035074.g004
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strains. The kinetics of visfatin-mediated R5 HIV inhibition
suggest that visfatin may act on the early steps in the viral life
cycle, such as viral entry into the cell.
Furthermore, p24 production in R5 HIV-infected MDM and
PBMC appeared to be modulated by visfatin treatment when
treated and untreated cells were infected at the same MOI
(adjusted to compensate for the reduction in infectivity under
treatment). This suggests that there might be further inhibitory
effects of visfatin downstream of entry, but occurring upstream of
integration of viral DNA in the host genome (as discussed in [20]).
Interestingly, this effect on reduction of p24 expression was not
observed in X4 HIV-infected cells, which may reflect differencesin
post-entryreplicationstagesbetweenR5andX4viruses[37,38,39].
Direct competition experiments indicated that visfatin does
indeed modulate the relative fitness of R5 versus X4 viral strains
in vitro. This notion was further supported by the clinical
observation that high visfatin expression is associated with
dominance of X4 HIV in the plasma, rather than R5.
These data suggest that visfatin can indeed to some extent
modulate the immune environment of the virus. Whether these in
vitro results can be translated to in vivo effects and whether visfatin
is directly involved in e.g. the coreceptor switch remains to be
elucidated. Evidently, the coreceptor switch cannot be attributed
to any individual factor (such as visfatin). Nevertheless, visfatin
could represent at least a peripheral parameter in the coreceptor
switch by facilitating X4 selection over R5 through effects on the
immune environment, in a fashion analogous to the documented
selection of X4 over R5 viruses during treatment with CCR5
inhibitors[40]. As such, it could constitute an additional parameter
in the different mathematical models of the coreceptor switch
currently being constructed [19,41,42].
Previously, we reported that visfatin may act on early events of
the viral life cycle, as the integration of proviral DNA is abrogated
by visfatin treatment, and that reduced binding of R5 HIV to the
cell membrane would be a plausible mechanism for this inhibitory
activity [20]. In this study, we demonstrated the direct binding of
visfatin to the CCR5 receptor, suggesting a mechanism for
inhibition of R5 but not X4 viral binding to the cell. Additionally,
the finding that visfatin binds directly to the CCR5 receptor may
shed light on the continuing controversy on the visfatin-receptor
interactions (e.g. [43]), and should be evaluated in the context of
the plethora of immune activities ascribed to this factor [44].
In conclusion, we suggest that the adipocytokine visfatin acts as
a novel monocyte-derived innate factor capable of deterring HIV
infection. As such, it represents one of the many host-derived
factors capable of exerting immune pressure on the virus. In
particular, the discriminatory activity of visfatin favouring X4 and
hampering R5 HIV may be of relevance in the HIV coreceptor
switch, for which it may at the very least represent a promising
candidate as biomarker.
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